一种新型循环 miRNA 标志物，用于非小细胞肺癌的早期诊断和预后预测。

A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.

机构信息

Department of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.

Department of Preventive Health Care, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.

出版信息

J Clin Lab Anal. 2020 Nov;34(11):e23505. doi: 10.1002/jcla.23505. Epub 2020 Aug 9.

DOI:10.1002/jcla.23505

PMID:33463758

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7676218/

Abstract

BACKGROUND

Non-small-cell lung cancer (NSCLC) is a significant public health issue worldwide. The aim of our study was to develop a serum miRNA-based molecular signature for the early detection and prognosis prediction of NSCLC.

METHODS

The significantly altered circulating miRNAs were profiled in GSE24709. The top ten upregulated miRNAs were miR-432, miR-942, miR-29c-5p, miR-601, miR-613, miR-520d-3p, miR-1261, miR-132-5p, miR-302b, and miR-154-5p, while the top ten downregulated miRNAs were miR-562, miR-18b, miR-9-3p, miR-154-3p, miR-20b, miR-18a, miR-487a, miR-20a, miR-103, and miR-144. Then, the top four upregulated serum miRNAs (miR-432, miR-942, miR-29c-5p, and miR-601) were validated by real-time quantitative PCR. The clinical significance of two candidate serum miRNAs, miR-942 and miR-601, was further explored.

RESULTS

Our results showed that the expression levels of serum miR-942 and serum miR-601 were significantly upregulated in NSCLC. In addition, serum miR-942 and serum miR-601 showed better performance than CEA, CYFRA21-1, and SCCA for early diagnosis of NSCLC. Combining serum miR-942 and serum miR-601 enhanced the efficacy of detecting early-stage NSCLC. Moreover, high serum miR-942 and serum miR-601 were both associated with adverse clinical variables and poor survival. The NSCLC patients with simultaneously high serum miR-942 and serum miR-601 suffered worst clinical outcome, while those with simultaneously low serum miR-942 and serum miR-601 had most favorable outcome. The multivariate analysis showed that serum miR-942 and serum miR-601 were independent prognostic factors for NSCLC.

CONCLUSIONS

Taken together, serum miR-942 and serum miR-601 might serve as a promising molecular signature for the early detection and prognosis prediction of NSCLC.

摘要

背景

非小细胞肺癌（NSCLC）是全球范围内的重大公共卫生问题。本研究旨在开发一种基于血清 miRNA 的分子特征，用于 NSCLC 的早期检测和预后预测。

方法

在 GSE24709 中分析显著改变的循环 miRNA。上调最明显的前 10 个 miRNA 是 miR-432、miR-942、miR-29c-5p、miR-601、miR-613、miR-520d-3p、miR-1261、miR-132-5p、miR-302b 和 miR-154-5p，而下调最明显的前 10 个 miRNA 是 miR-562、miR-18b、miR-9-3p、miR-154-3p、miR-20b、miR-18a、miR-487a、miR-20a、miR-103 和 miR-144。然后，通过实时定量 PCR 验证前 4 个上调的血清 miRNA（miR-432、miR-942、miR-29c-5p 和 miR-601）。进一步探讨了候选血清 miRNA 两个 miR-942 和 miR-601 的临床意义。

结果

结果显示，血清 miR-942 和血清 miR-601 的表达水平在 NSCLC 中显著上调。此外，血清 miR-942 和血清 miR-601 用于 NSCLC 的早期诊断，其表现优于 CEA、CYFRA21-1 和 SCCA。联合检测血清 miR-942 和血清 miR-601 增强了早期诊断 NSCLC 的效果。此外，高血清 miR-942 和血清 miR-601 均与不良临床变量和预后不良相关。同时高血清 miR-942 和血清 miR-601 的 NSCLC 患者临床结局最差，而同时低血清 miR-942 和血清 miR-601 的患者临床结局最好。多变量分析显示，血清 miR-942 和血清 miR-601 是 NSCLC 的独立预后因素。